<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00791661</url>
  </required_header>
  <id_info>
    <org_study_id>1006-005</org_study_id>
    <secondary_id>2008_584</secondary_id>
    <nct_id>NCT00791661</nct_id>
  </id_info>
  <brief_title>MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005)</brief_title>
  <official_title>A Single Dose Clinical Trial to Study the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-1006 in Japanese Subject With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single rising dose study to assess the safety, tolerability, pharmacokinetics and
      pharmacodynamics of MK-1006 in Japanese participants with Type 2 Diabetes Mellitus (T2DM).
      The primary hypothesis of the study is that single doses of MK-1006 will be sufficiently safe
      and well tolerated, based on the assessment of clinical and laboratory evaluations and
      adverse experiences, in Japanese participants with T2DM.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experienced at Least One Adverse Event</measure>
    <time_frame>from the time of the run-in period prior to the first dose of study drug through the end of the poststudy period (up to approximately 31 days)</time_frame>
    <description>An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued Treatment Due to an Adverse Event</measure>
    <time_frame>up to approximately 17 days</time_frame>
    <description>An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Area Under the Plasma Concentration Curve From Time Zero to Infinity(AUC[0-∞]) After a Single Dose of MK-1006</measure>
    <time_frame>Approximately 96 hours for MK-1006 15mg, 30 mg, 45 mg, 60 mg, 60 mg fed (predose up to approximately 96 hours postdose); approximately 120 hours for MK-1006 80 mg, 100 mg, 140 mg, and 170 mg (predose up to 120 hours postdose)</time_frame>
    <description>AUC(0-∞) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. The placebo group was not evaluated for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Area Under the Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After a Single Dose of MK-1006</measure>
    <time_frame>Approximately 96 hours for MK-1006 15mg, 30 mg, 45 mg, 60 mg, 60 mg fed (predose up to approximately 96 hours postdose); approximately 120 hours for MK-1006 80 mg, 100 mg, 140 mg, and 170 mg (predose up to 120 hours postdose)</time_frame>
    <description>AUC(0 to 24 hours) was estimated by determining the total area under the curve of the concentration versus time curve to 24 hours post dose. The placebo group was not evaluated for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Maximum Plasma Concentration (Cmax) After a Single Dose of MK-1006</measure>
    <time_frame>Approximately 96 hours for MK-1006 15mg, 30 mg, 45 mg, 60 mg, 60 mg fed (predose up to approximately 96 hours postdose); approximately 120 hours for MK-1006 80 mg, 100 mg, 140 mg, and 170 mg (predose up to 120 hours postdose)</time_frame>
    <description>The placebo group was not evaluated for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Maximum Plasma Concentration (Tmax) After a Single Dose of MK-1006</measure>
    <time_frame>Approximately 96 hours for MK-1006 15mg, 30 mg, 45 mg, 60 mg, 60 mg fed (predose up to approximately 96 hours postdose); approximately 120 hours for MK-1006 80 mg, 100 mg, 140 mg, and 170 mg (predose up to 120 hours postdose)</time_frame>
    <description>The placebo group was not evaluated for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-life (T 1/2) After a Single Dose of MK-1006</measure>
    <time_frame>Approximately 96 hours for MK-1006 15mg, 30 mg, 45 mg, 60 mg, 60 mg fed (predose up to approximately 96 hours postdose); approximately 120 hours for MK-1006 80 mg, 100 mg, 140 mg, and 170 mg (predose up to 120 hours postdose)</time_frame>
    <description>The apparent half-life was defined as the time required for the plasma concentration of MK-1006 to decrease 50% in the final stage of its elimination. The means and standard deviations displayed as are the harmonic means and pseudo-standard deviations, respectively. The placebo group was not evaluated for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour Weighted Mean Glucose (WMG) Concentration</measure>
    <time_frame>Up to 36 hours</time_frame>
    <description>Weighted mean glucose concentration was calculated as the 24-hour area under the plasma concentration-time curve divided by 24.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes Mellitus, Non-Insulin-Dependent</condition>
  <arm_group>
    <arm_group_label>Panel A: MK-1006 15/30/45</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single rising dose of MK-1006 (dosed at 15 mg, 30 mg, and 45 mg) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B: MK-1006 60/80/60 fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single rising dose of MK-1006 (dosed at 60 mg, 80 mg, and 60 mg fed state) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel C: MK-1006 100/140/170</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single rising dose of MK-1006 (dosed at 100 mg, 140 mg, and 170 mg) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-1006</intervention_name>
    <description>MK-1006 capsules in single oral doses beginning at 15 mg and rising to 45 mg in Panel A, beginning at 60 mg and rising to 80 mg and 60 mg fed state in Panel B, or beginning at 100 mg and rising to 170 mg in Panel C.</description>
    <arm_group_label>Panel A: MK-1006 15/30/45</arm_group_label>
    <arm_group_label>Panel B: MK-1006 60/80/60 fed</arm_group_label>
    <arm_group_label>Panel C: MK-1006 100/140/170</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to MK-1006 in a single oral dose</description>
    <arm_group_label>Panel A: MK-1006 15/30/45</arm_group_label>
    <arm_group_label>Panel B: MK-1006 60/80/60 fed</arm_group_label>
    <arm_group_label>Panel C: MK-1006 100/140/170</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese male or female between 20 to 64 years of age

          -  Diagnosis of type 2 diabetes

          -  Patient is being treated with diet and exercise alone or single oral
             anti-hyperglycemic agent

        Exclusion Criteria:

          -  Subject has a history of type 1 diabetes mellitus

          -  Subject has a clinical diagnosis of glaucoma

          -  Subject has donated blood or participated in another clinical study in the past 12
             weeks

          -  Subject is a regular user of any illicit drugs or has a history of drug, including
             alcohol, abuse in the past 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2008</study_first_submitted>
  <study_first_submitted_qc>November 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2008</study_first_posted>
  <results_first_submitted>September 7, 2012</results_first_submitted>
  <results_first_submitted_qc>September 7, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 10, 2012</results_first_posted>
  <last_update_submitted>January 6, 2016</last_update_submitted>
  <last_update_submitted_qc>January 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Panel A: MK-1006 15/30/45</title>
          <description>Participants received a single dose of MK-1006 (dosed at 15 mg, 30 mg, and 45 mg) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.</description>
        </group>
        <group group_id="P2">
          <title>Panel B: MK-1006 60/80/60 Fed</title>
          <description>Participants received a single dose of MK-1006 (dosed at 60 mg, 80 mg, and 60 mg fed state) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.</description>
        </group>
        <group group_id="P3">
          <title>Panel C: MK-1006 100/140/170</title>
          <description>Participants received a single dose of MK-1006 (dosed at 100 mg, 140 mg, and 170 mg) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received MK-1006</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Matching Placebo to MK-1006</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>7 Day Wash-out</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Clinical Laboratory Test</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received MK-1006</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Matching Placebo to MK-1006</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>7 Day Wash-out</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received MK-1006</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Matching Placebo to MK-1006</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Panel A: MK-1006 15/30/45</title>
          <description>Participants received a single dose of MK-1006 (dosed at 15 mg, 30 mg, and 45 mg) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.</description>
        </group>
        <group group_id="B2">
          <title>Panel B: MK-1006 60/80/60 Fed</title>
          <description>Participants received a single dose of MK-1006 (dosed at 60 mg, 80 mg, and 60 mg fed state) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.</description>
        </group>
        <group group_id="B3">
          <title>Panel C: MK-1006 100/140/170</title>
          <description>Participants received a single dose of MK-1006 (dosed at 100 mg, 140 mg, and 170 mg) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;41 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 41 years and &lt;=64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced at Least One Adverse Event</title>
        <description>An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product.</description>
        <time_frame>from the time of the run-in period prior to the first dose of study drug through the end of the poststudy period (up to approximately 31 days)</time_frame>
        <population>Participants who received study drug. The same participant may appear in more than one treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1006 15 mg</title>
            <description>Participants received a single dose of MK-1006 15 mg</description>
          </group>
          <group group_id="O2">
            <title>MK-1006 30 mg</title>
            <description>Participants received a single dose of MK-1006 30 mg</description>
          </group>
          <group group_id="O3">
            <title>MK-1006 45 mg</title>
            <description>Participants received a single dose of MK-1006 45 mg</description>
          </group>
          <group group_id="O4">
            <title>MK-1006 60 mg</title>
            <description>Participants received a single dose of MK-1006 60 mg</description>
          </group>
          <group group_id="O5">
            <title>MK-1006 60 mg Fed</title>
            <description>Participants received a single dose of MK-1006 60 mg following consumption of a standard Japanese breakfast</description>
          </group>
          <group group_id="O6">
            <title>MK-1006 80 mg</title>
            <description>Participants received a single dose of MK-1006 80 mg</description>
          </group>
          <group group_id="O7">
            <title>MK-1006 100 mg</title>
            <description>Participants received a single dose of MK-1006 100 mg</description>
          </group>
          <group group_id="O8">
            <title>MK-1006 140 mg</title>
            <description>Participants received a single dose of MK-1006 140 mg</description>
          </group>
          <group group_id="O9">
            <title>MK-1006 170 mg</title>
            <description>Participants received a single dose of MK-1006 170 mg</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Participants received matching placebo to MK-1006</description>
          </group>
          <group group_id="O11">
            <title>Placebo Fed</title>
            <description>Participants received matching placebo to MK-1006 following consumption of a standard Japanese breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced at Least One Adverse Event</title>
          <description>An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product.</description>
          <population>Participants who received study drug. The same participant may appear in more than one treatment arm.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="15"/>
                <count group_id="O11" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Area Under the Plasma Concentration Curve From Time Zero to Infinity(AUC[0-∞]) After a Single Dose of MK-1006</title>
        <description>AUC(0-∞) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. The placebo group was not evaluated for this outcome measure.</description>
        <time_frame>Approximately 96 hours for MK-1006 15mg, 30 mg, 45 mg, 60 mg, 60 mg fed (predose up to approximately 96 hours postdose); approximately 120 hours for MK-1006 80 mg, 100 mg, 140 mg, and 170 mg (predose up to 120 hours postdose)</time_frame>
        <population>Participants received a singe dose of MK-1006 following an overnight fast (for approximately 10 hours), except the MK-1006 60 mg fed arm in which participants received a single dose of MK-1006 following the consumption of a standard Japanese breakfast. The same participant may appear in more than one treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1006 15 mg</title>
            <description>Participants received a single dose of MK-1006 15 mg</description>
          </group>
          <group group_id="O2">
            <title>MK-1006 30 mg</title>
            <description>Participants received a single dose of MK-1006 30 mg</description>
          </group>
          <group group_id="O3">
            <title>MK-1006 45 mg</title>
            <description>Participants received a single dose of MK-1006 45 mg</description>
          </group>
          <group group_id="O4">
            <title>MK-1006 60 mg</title>
            <description>Participants received a single dose of MK-1006 60 mg</description>
          </group>
          <group group_id="O5">
            <title>MK-1006 60 mg Fed</title>
            <description>Participants received a single dose of MK-1006 60 mg following consumption of a standard Japanese breakfast</description>
          </group>
          <group group_id="O6">
            <title>MK-1006 80 mg</title>
            <description>Participants received a single dose of MK-1006 80 mg</description>
          </group>
          <group group_id="O7">
            <title>MK-1006 100 mg</title>
            <description>Participants received a single dose of MK-1006 100 mg</description>
          </group>
          <group group_id="O8">
            <title>MK-1006 140 mg</title>
            <description>Participants received a single dose of MK-1006 140 mg</description>
          </group>
          <group group_id="O9">
            <title>MK-1006 170 mg</title>
            <description>Participants received a single dose of MK-1006 170 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Area Under the Plasma Concentration Curve From Time Zero to Infinity(AUC[0-∞]) After a Single Dose of MK-1006</title>
          <description>AUC(0-∞) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. The placebo group was not evaluated for this outcome measure.</description>
          <population>Participants received a singe dose of MK-1006 following an overnight fast (for approximately 10 hours), except the MK-1006 60 mg fed arm in which participants received a single dose of MK-1006 following the consumption of a standard Japanese breakfast. The same participant may appear in more than one treatment arm.</population>
          <units>nM*hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="489" spread="134"/>
                    <measurement group_id="O2" value="904" spread="249"/>
                    <measurement group_id="O3" value="1900" spread="384"/>
                    <measurement group_id="O4" value="2350" spread="897"/>
                    <measurement group_id="O5" value="2100" spread="556"/>
                    <measurement group_id="O6" value="3820" spread="1300"/>
                    <measurement group_id="O7" value="6060" spread="2180"/>
                    <measurement group_id="O8" value="6920" spread="1420"/>
                    <measurement group_id="O9" value="9560" spread="3490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio (fed/fasted)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Area Under the Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After a Single Dose of MK-1006</title>
        <description>AUC(0 to 24 hours) was estimated by determining the total area under the curve of the concentration versus time curve to 24 hours post dose. The placebo group was not evaluated for this outcome measure.</description>
        <time_frame>Approximately 96 hours for MK-1006 15mg, 30 mg, 45 mg, 60 mg, 60 mg fed (predose up to approximately 96 hours postdose); approximately 120 hours for MK-1006 80 mg, 100 mg, 140 mg, and 170 mg (predose up to 120 hours postdose)</time_frame>
        <population>Participants received a singe dose of MK-1006 following an overnight fast (for approximately 10 hours), except the MK-1006 60 mg fed arm in which participants received a single dose of MK-1006 following the consumption of a standard Japanese breakfast. The same participant may appear in more than one treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1006 15 mg</title>
            <description>Participants received a single dose of MK-1006 15 mg</description>
          </group>
          <group group_id="O2">
            <title>MK-1006 30 mg</title>
            <description>Participants received a single dose of MK-1006 30 mg</description>
          </group>
          <group group_id="O3">
            <title>MK-1006 45 mg</title>
            <description>Participants received a single dose of MK-1006 45 mg</description>
          </group>
          <group group_id="O4">
            <title>MK-1006 60 mg</title>
            <description>Participants received a single dose of MK-1006 60 mg</description>
          </group>
          <group group_id="O5">
            <title>MK-1006 60 mg Fed</title>
            <description>Participants received a single dose of MK-1006 60 mg following consumption of a standard Japanese breakfast</description>
          </group>
          <group group_id="O6">
            <title>MK-1006 80 mg</title>
            <description>Participants received a single dose of MK-1006 80 mg</description>
          </group>
          <group group_id="O7">
            <title>MK-1006 100 mg</title>
            <description>Participants received a single dose of MK-1006 100 mg</description>
          </group>
          <group group_id="O8">
            <title>MK-1006 140 mg</title>
            <description>Participants received a single dose of MK-1006 140 mg</description>
          </group>
          <group group_id="O9">
            <title>MK-1006 170 mg</title>
            <description>Participants received a single dose of MK-1006 170 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Area Under the Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After a Single Dose of MK-1006</title>
          <description>AUC(0 to 24 hours) was estimated by determining the total area under the curve of the concentration versus time curve to 24 hours post dose. The placebo group was not evaluated for this outcome measure.</description>
          <population>Participants received a singe dose of MK-1006 following an overnight fast (for approximately 10 hours), except the MK-1006 60 mg fed arm in which participants received a single dose of MK-1006 following the consumption of a standard Japanese breakfast. The same participant may appear in more than one treatment arm.</population>
          <units>nM*hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="358" spread="116"/>
                    <measurement group_id="O2" value="665" spread="186"/>
                    <measurement group_id="O3" value="1450" spread="315"/>
                    <measurement group_id="O4" value="1720" spread="782"/>
                    <measurement group_id="O5" value="1440" spread="342"/>
                    <measurement group_id="O6" value="2790" spread="1000"/>
                    <measurement group_id="O7" value="4610" spread="1730"/>
                    <measurement group_id="O8" value="5370" spread="1330"/>
                    <measurement group_id="O9" value="7540" spread="3010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Maximum Plasma Concentration (Cmax) After a Single Dose of MK-1006</title>
        <description>The placebo group was not evaluated for this outcome measure.</description>
        <time_frame>Approximately 96 hours for MK-1006 15mg, 30 mg, 45 mg, 60 mg, 60 mg fed (predose up to approximately 96 hours postdose); approximately 120 hours for MK-1006 80 mg, 100 mg, 140 mg, and 170 mg (predose up to 120 hours postdose)</time_frame>
        <population>Participants received a singe dose of MK-1006 following an overnight fast (for approximately 10 hours), except the MK-1006 60 mg fed arm in which participants received a single dose of MK-1006 following the consumption of a standard Japanese breakfast. The same participant may appear in more than one treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1006 15 mg</title>
            <description>Participants received a single dose of MK-1006 15 mg</description>
          </group>
          <group group_id="O2">
            <title>MK-1006 30 mg</title>
            <description>Participants received a single dose of MK-1006 30 mg</description>
          </group>
          <group group_id="O3">
            <title>MK-1006 45 mg</title>
            <description>Participants received a single dose of MK-1006 45 mg</description>
          </group>
          <group group_id="O4">
            <title>MK-1006 60 mg</title>
            <description>Participants received a single dose of MK-1006 60 mg</description>
          </group>
          <group group_id="O5">
            <title>MK-1006 60 mg Fed</title>
            <description>Participants received a single dose of MK-1006 60 mg following consumption of a standard Japanese breakfast</description>
          </group>
          <group group_id="O6">
            <title>MK-1006 80 mg</title>
            <description>Participants received a single dose of MK-1006 80 mg</description>
          </group>
          <group group_id="O7">
            <title>MK-1006 100 mg</title>
            <description>Participants received a single dose of MK-1006 100 mg</description>
          </group>
          <group group_id="O8">
            <title>MK-1006 140 mg</title>
            <description>Participants received a single dose of MK-1006 140 mg</description>
          </group>
          <group group_id="O9">
            <title>MK-1006 170 mg</title>
            <description>Participants received a single dose of MK-1006 170 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Maximum Plasma Concentration (Cmax) After a Single Dose of MK-1006</title>
          <description>The placebo group was not evaluated for this outcome measure.</description>
          <population>Participants received a singe dose of MK-1006 following an overnight fast (for approximately 10 hours), except the MK-1006 60 mg fed arm in which participants received a single dose of MK-1006 following the consumption of a standard Japanese breakfast. The same participant may appear in more than one treatment arm.</population>
          <units>nM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3" spread="16.3"/>
                    <measurement group_id="O2" value="75.4" spread="23.9"/>
                    <measurement group_id="O3" value="169" spread="49.8"/>
                    <measurement group_id="O4" value="185" spread="102"/>
                    <measurement group_id="O5" value="141" spread="41"/>
                    <measurement group_id="O6" value="310" spread="172"/>
                    <measurement group_id="O7" value="514" spread="180"/>
                    <measurement group_id="O8" value="628" spread="205"/>
                    <measurement group_id="O9" value="912" spread="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio (fed/fasted)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Maximum Plasma Concentration (Tmax) After a Single Dose of MK-1006</title>
        <description>The placebo group was not evaluated for this outcome measure.</description>
        <time_frame>Approximately 96 hours for MK-1006 15mg, 30 mg, 45 mg, 60 mg, 60 mg fed (predose up to approximately 96 hours postdose); approximately 120 hours for MK-1006 80 mg, 100 mg, 140 mg, and 170 mg (predose up to 120 hours postdose)</time_frame>
        <population>Participants received a singe dose of MK-1006 following an overnight fast (for approximately 10 hours), except the MK-1006 60 mg fed arm in which participants received a single dose of MK-1006 following the consumption of a standard Japanese breakfast. The same participant may appear in more than one treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1006 15 mg</title>
            <description>Participants received a single dose of MK-1006 15 mg</description>
          </group>
          <group group_id="O2">
            <title>MK-1006 30 mg</title>
            <description>Participants received a single dose of MK-1006 30 mg</description>
          </group>
          <group group_id="O3">
            <title>MK-1006 45 mg</title>
            <description>Participants received a single dose of MK-1006 45 mg</description>
          </group>
          <group group_id="O4">
            <title>MK-1006 60 mg</title>
            <description>Participants received a single dose of MK-1006 60 mg</description>
          </group>
          <group group_id="O5">
            <title>MK-1006 60 mg Fed</title>
            <description>Participants received a single dose of MK-1006 60 mg following consumption of a standard Japanese breakfast</description>
          </group>
          <group group_id="O6">
            <title>MK-1006 80 mg</title>
            <description>Participants received a single dose of MK-1006 80 mg</description>
          </group>
          <group group_id="O7">
            <title>MK-1006 100 mg</title>
            <description>Participants received a single dose of MK-1006 100 mg</description>
          </group>
          <group group_id="O8">
            <title>MK-1006 140 mg</title>
            <description>Participants received a single dose of MK-1006 140 mg</description>
          </group>
          <group group_id="O9">
            <title>MK-1006 170 mg</title>
            <description>Participants received a single dose of MK-1006 170 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Maximum Plasma Concentration (Tmax) After a Single Dose of MK-1006</title>
          <description>The placebo group was not evaluated for this outcome measure.</description>
          <population>Participants received a singe dose of MK-1006 following an overnight fast (for approximately 10 hours), except the MK-1006 60 mg fed arm in which participants received a single dose of MK-1006 following the consumption of a standard Japanese breakfast. The same participant may appear in more than one treatment arm.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O4" value="4.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O5" value="5.0" lower_limit="3.0" upper_limit="6.0"/>
                    <measurement group_id="O6" value="4.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O7" value="3.5" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O8" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O9" value="3.0" lower_limit="1.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Half-life (T 1/2) After a Single Dose of MK-1006</title>
        <description>The apparent half-life was defined as the time required for the plasma concentration of MK-1006 to decrease 50% in the final stage of its elimination. The means and standard deviations displayed as are the harmonic means and pseudo-standard deviations, respectively. The placebo group was not evaluated for this outcome measure.</description>
        <time_frame>Approximately 96 hours for MK-1006 15mg, 30 mg, 45 mg, 60 mg, 60 mg fed (predose up to approximately 96 hours postdose); approximately 120 hours for MK-1006 80 mg, 100 mg, 140 mg, and 170 mg (predose up to 120 hours postdose)</time_frame>
        <population>Participants received a singe dose of MK-1006 following an overnight fast (for approximately 10 hours), except the MK-1006 60 mg fed arm in which participants received a single dose of MK-1006 following the consumption of a standard Japanese breakfast. The same participant may appear in more than one treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1006 15 mg</title>
            <description>Participants received a single dose of MK-1006 15 mg</description>
          </group>
          <group group_id="O2">
            <title>MK-1006 30 mg</title>
            <description>Participants received a single dose of MK-1006 30 mg</description>
          </group>
          <group group_id="O3">
            <title>MK-1006 45 mg</title>
            <description>Participants received a single dose of MK-1006 45 mg</description>
          </group>
          <group group_id="O4">
            <title>MK-1006 60 mg</title>
            <description>Participants received a single dose of MK-1006 60 mg</description>
          </group>
          <group group_id="O5">
            <title>MK-1006 60 mg Fed</title>
            <description>Participants received a single dose of MK-1006 60 mg following consumption of a standard Japanese breakfast</description>
          </group>
          <group group_id="O6">
            <title>MK-1006 80 mg</title>
            <description>Participants received a single dose of MK-1006 80 mg</description>
          </group>
          <group group_id="O7">
            <title>MK-1006 100 mg</title>
            <description>Participants received a single dose of MK-1006 100 mg</description>
          </group>
          <group group_id="O8">
            <title>MK-1006 140 mg</title>
            <description>Participants received a single dose of MK-1006 140 mg</description>
          </group>
          <group group_id="O9">
            <title>MK-1006 170 mg</title>
            <description>Participants received a single dose of MK-1006 170 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life (T 1/2) After a Single Dose of MK-1006</title>
          <description>The apparent half-life was defined as the time required for the plasma concentration of MK-1006 to decrease 50% in the final stage of its elimination. The means and standard deviations displayed as are the harmonic means and pseudo-standard deviations, respectively. The placebo group was not evaluated for this outcome measure.</description>
          <population>Participants received a singe dose of MK-1006 following an overnight fast (for approximately 10 hours), except the MK-1006 60 mg fed arm in which participants received a single dose of MK-1006 following the consumption of a standard Japanese breakfast. The same participant may appear in more than one treatment arm.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" spread="5.5"/>
                    <measurement group_id="O2" value="18.5" spread="3.8"/>
                    <measurement group_id="O3" value="19.1" spread="2.2"/>
                    <measurement group_id="O4" value="18.5" spread="3.5"/>
                    <measurement group_id="O5" value="17.0" spread="1.7"/>
                    <measurement group_id="O6" value="21.2" spread="2.9"/>
                    <measurement group_id="O7" value="22.1" spread="5.2"/>
                    <measurement group_id="O8" value="20.7" spread="2.6"/>
                    <measurement group_id="O9" value="21.5" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinued Treatment Due to an Adverse Event</title>
        <description>An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product.</description>
        <time_frame>up to approximately 17 days</time_frame>
        <population>Participants who received study drug. The same participant may appear in more than one treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1006 15 mg</title>
            <description>Participants received a single dose of MK-1006 15 mg</description>
          </group>
          <group group_id="O2">
            <title>MK-1006 30 mg</title>
            <description>Participants received a single dose of MK-1006 30 mg</description>
          </group>
          <group group_id="O3">
            <title>MK-1006 45 mg</title>
            <description>Participants received a single dose of MK-1006 45 mg</description>
          </group>
          <group group_id="O4">
            <title>MK-1006 60 mg</title>
            <description>Participants received a single dose of MK-1006 60 mg</description>
          </group>
          <group group_id="O5">
            <title>MK-1006 60 mg Fed</title>
            <description>Participants received a single dose of MK-1006 60 mg following consumption of a standard Japanese breakfast</description>
          </group>
          <group group_id="O6">
            <title>MK-1006 80 mg</title>
            <description>Participants received a single dose of MK-1006 80 mg</description>
          </group>
          <group group_id="O7">
            <title>MK-1006 100 mg</title>
            <description>Participants received a single dose of MK-1006 100 mg</description>
          </group>
          <group group_id="O8">
            <title>MK-1006 140 mg</title>
            <description>Participants received a single dose of MK-1006 140 mg</description>
          </group>
          <group group_id="O9">
            <title>MK-1006 170 mg</title>
            <description>Participants received a single dose of MK-1006 170 mg</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Participants received matching placebo to MK-1006</description>
          </group>
          <group group_id="O11">
            <title>Placebo Fed</title>
            <description>Participants received matching placebo to MK-1006 following consumption of a standard Japanese breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Treatment Due to an Adverse Event</title>
          <description>An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product.</description>
          <population>Participants who received study drug. The same participant may appear in more than one treatment arm.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="15"/>
                <count group_id="O11" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24-hour Weighted Mean Glucose (WMG) Concentration</title>
        <description>Weighted mean glucose concentration was calculated as the 24-hour area under the plasma concentration-time curve divided by 24.</description>
        <time_frame>Up to 36 hours</time_frame>
        <population>Participants received a singe dose of MK-1006 following an overnight fast (for approximately 10 hours), except the MK-1006 60 mg fed arm in which participants received a single dose of MK-1006 following the consumption of a standard Japanese breakfast. The same participant may appear in more than one treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1006 15 mg</title>
            <description>Participants received a single dose of MK-1006 15 mg</description>
          </group>
          <group group_id="O2">
            <title>MK-1006 30 mg</title>
            <description>Participants received a single dose of MK-1006 30 mg</description>
          </group>
          <group group_id="O3">
            <title>MK-1006 45 mg</title>
            <description>Participants received a single dose of MK-1006 45 mg</description>
          </group>
          <group group_id="O4">
            <title>MK-1006 60 mg</title>
            <description>Participants received a single dose of MK-1006 60 mg</description>
          </group>
          <group group_id="O5">
            <title>MK-1006 60 mg Fed</title>
            <description>Participants received a single dose of MK-1006 60 mg following consumption of a standard Japanese breakfast</description>
          </group>
          <group group_id="O6">
            <title>MK-1006 80 mg</title>
            <description>Participants received a single dose of MK-1006 80 mg</description>
          </group>
          <group group_id="O7">
            <title>MK-1006 100 mg</title>
            <description>Participants received a single dose of MK-1006 100 mg</description>
          </group>
          <group group_id="O8">
            <title>MK-1006 140 mg</title>
            <description>Participants received a single dose of MK-1006 140 mg</description>
          </group>
          <group group_id="O9">
            <title>MK-1006 170 mg</title>
            <description>Participants received a single dose of MK-1006 170 mg</description>
          </group>
          <group group_id="O10">
            <title>Placebo</title>
            <description>Participants received matching placebo to MK-1006</description>
          </group>
          <group group_id="O11">
            <title>Placebo Fed</title>
            <description>Participants received matching placebo to MK-1006 following consumption of a standard Japanese breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>24-hour Weighted Mean Glucose (WMG) Concentration</title>
          <description>Weighted mean glucose concentration was calculated as the 24-hour area under the plasma concentration-time curve divided by 24.</description>
          <population>Participants received a singe dose of MK-1006 following an overnight fast (for approximately 10 hours), except the MK-1006 60 mg fed arm in which participants received a single dose of MK-1006 following the consumption of a standard Japanese breakfast. The same participant may appear in more than one treatment arm.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="15"/>
                <count group_id="O11" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.2" spread="50.8" lower_limit="188.0" upper_limit="224.4"/>
                    <measurement group_id="O2" value="197.6" spread="40.9" lower_limit="179.1" upper_limit="216.1"/>
                    <measurement group_id="O3" value="188.6" spread="28.0" lower_limit="170.3" upper_limit="206.9"/>
                    <measurement group_id="O4" value="178.0" spread="24.7" lower_limit="159.5" upper_limit="196.6"/>
                    <measurement group_id="O5" value="165.7" spread="26.7" lower_limit="146.8" upper_limit="184.6"/>
                    <measurement group_id="O6" value="156.7" spread="21.7" lower_limit="138.2" upper_limit="175.3"/>
                    <measurement group_id="O7" value="199.0" spread="33.6" lower_limit="180.7" upper_limit="217.3"/>
                    <measurement group_id="O8" value="170.4" spread="25.8" lower_limit="148.9" upper_limit="191.9"/>
                    <measurement group_id="O9" value="154.9" spread="21.4" lower_limit="134.8" upper_limit="175.0"/>
                    <measurement group_id="O10" value="214.3" spread="34.5" lower_limit="202.9" upper_limit="225.7"/>
                    <measurement group_id="O11" value="185.4" spread="17.7" lower_limit="159.5" upper_limit="211.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>At one or more well tolerated single doses of MK-1006, the 24-hour weighted mean glucose concentration is expected to be at least 25 mg/dL lower than placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.368</p_value>
            <p_value_desc>A step down procedure starting with the highest tolerated dose was implemented.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Based on mixed effect model with glucose baseline, panel and treatment-within-panel as fixed effects and participant-within panel as a random effect.</method_desc>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-8.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.0</ci_lower_limit>
            <ci_upper_limit>6.8</ci_upper_limit>
            <estimate_desc>The calculation used to determine the difference in least squares mean (LS mean) was LS mean for MK-1006 15 mg minus LS mean for placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>At one or more well tolerated single doses of MK-1006, the 24-hour weighted mean glucose concentration is expected to be at least 25 mg/dL lower than placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.079</p_value>
            <p_value_desc>A step down procedure starting with the highest tolerated dose was implemented.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Based on mixed effect model with glucose baseline, panel and treatment-within-panel as fixed effects and participant-within panel as a random effect.</method_desc>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-16.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.2</ci_lower_limit>
            <ci_upper_limit>-1.1</ci_upper_limit>
            <estimate_desc>The calculation used to determine the difference in least squares mean (LS mean) was LS mean for MK-1006 30 mg minus LS mean for placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>At one or more well tolerated single doses of MK-1006, the 24-hour weighted mean glucose concentration is expected to be at least 25 mg/dL lower than placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>A step down procedure starting with the highest tolerated dose was implemented.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Based on mixed effect model with glucose baseline, panel and treatment-within-panel as fixed effects and participant-within panel as a random effect.</method_desc>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-25.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.9</ci_lower_limit>
            <ci_upper_limit>-10.5</ci_upper_limit>
            <estimate_desc>The calculation used to determine the difference in least squares mean (LS mean) was LS mean for MK-1006 45 mg minus LS mean for placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>At one or more well tolerated single doses of MK-1006, the 24-hour weighted mean glucose concentration is expected to be at least 25 mg/dL lower than placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>A step down procedure starting with the highest tolerated dose was implemented.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Based on mixed effect model with glucose baseline, panel and treatment-within-panel as fixed effects and participant-within panel as a random effect.</method_desc>
            <param_type>Diffrence in least squares mean</param_type>
            <param_value>-36.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.0</ci_lower_limit>
            <ci_upper_limit>-20.5</ci_upper_limit>
            <estimate_desc>The calculation used to determine the difference in least squares mean (LS mean) was LS mean for MK-1006 60 mg minus LS mean for placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.147</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Based on mixed effect model with glucose baseline, panel and treatment-within-panel as fixed effects and participant-within panel as a random effect.</method_desc>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-19.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.2</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
            <estimate_desc>The calculation used to determine the difference in least squares mean (LS mean) was LS mean for MK-1006 60 mg fed minus LS mean for placebo fed.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.114</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Based on mixed effect model with glucose baseline, panel and treatment-within-panel as fixed effects and participant-within panel as a random effect.</method_desc>
            <param_type>Difference in least squares mean</param_type>
            <param_value>12.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>25.2</ci_upper_limit>
            <estimate_desc>Difference in least squares mean (LS mean) was calculated as LS mean for MK-1006 60 mg minus LS mean for MK-1006 60 mg fed.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O11</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Based on mixed effect model with glucose baseline, panel and treatment-within-panel as fixed effects and participant-within panel as a random effect.</method_desc>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-28.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.9</ci_lower_limit>
            <ci_upper_limit>-7.9</ci_upper_limit>
            <estimate_desc>The calculation used to determine the difference in least squares mean (LS mean) was LS mean for placebo fed minus LS mean for placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>At one or more well tolerated single doses of MK-1006, the 24-hour weighted mean glucose concentration is expected to be at least 25 mg/dL lower than placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>A step down procedure starting with the highest tolerated dose was implemented.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Based on mixed effect model with glucose baseline, panel and treatment-within-panel as fixed effects and participant-within panel as a random effect.</method_desc>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-57.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-73.3</ci_lower_limit>
            <ci_upper_limit>-41.9</ci_upper_limit>
            <estimate_desc>The calculation used to determine the difference in least squares mean (LS mean) was LS mean for MK-1006 80 mg minus LS mean for placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>At one or more well tolerated single doses of MK-1006, the 24-hour weighted mean glucose concentration is expected to be at least 25 mg/dL lower than placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.099</p_value>
            <p_value_desc>A step down procedure starting with the highest tolerated dose was implemented.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Based on mixed effect model with glucose baseline, panel and treatment-within-panel as fixed effects and participant-within panel as a random effect.</method_desc>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-15.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.5</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
            <estimate_desc>The calculation used to determine the difference in least squares mean (LS mean) was LS mean for MK-1006 100 mg minus LS mean for placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>At one or more well tolerated single doses of MK-1006, the 24-hour weighted mean glucose concentration is expected to be at least 25 mg/dL lower than placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>A step down procedure starting with the highest tolerated dose was implemented.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Based on mixed effect model with glucose baseline, panel and treatment-within-panel as fixed effects and participant-within panel as a random effect.</method_desc>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-43.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-60.8</ci_lower_limit>
            <ci_upper_limit>-27.0</ci_upper_limit>
            <estimate_desc>The calculation used to determine the difference in least squares mean (LS mean) was LS mean for MK-1006 140 mg minus LS mean for placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>At one or more well tolerated single doses of MK-1006, the 24-hour weighted mean glucose concentration is expected to be at least 25 mg/dL lower than placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>A step down procedure starting with the highest tolerated dose was implemented.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Based on mixed effect model with glucose baseline, panel and treatment-within-panel as fixed effects and participant-within panel as a random effect.</method_desc>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-59.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-75.1</ci_lower_limit>
            <ci_upper_limit>-43.7</ci_upper_limit>
            <estimate_desc>The calculation used to determine the difference in least squares mean (LS mean) was LS mean for MK-1006 170 mg minus LS mean for placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same participant may appear in more than one treatment arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>MK-1006 15 mg</title>
          <description>Participants received a single dose of MK-1006 15 mg</description>
        </group>
        <group group_id="E2">
          <title>MK-1006 30 mg</title>
          <description>Participants received a single dose of MK-1006 30 mg</description>
        </group>
        <group group_id="E3">
          <title>MK-1006 45 mg</title>
          <description>Participants received a single dose of MK-1006 45 mg</description>
        </group>
        <group group_id="E4">
          <title>MK-1006 60 mg</title>
          <description>Participants received a single dose of MK-1006 60 mg</description>
        </group>
        <group group_id="E5">
          <title>MK-1006 60 mg Fed</title>
          <description>Participants received a single dose of MK-1006 60 mg following consumption of a standard Japanese breakfast</description>
        </group>
        <group group_id="E6">
          <title>MK-1006 80 mg</title>
          <description>Participants received a single dose of MK-1006 80 mg</description>
        </group>
        <group group_id="E7">
          <title>MK-1006 100 mg</title>
          <description>Participants received a single dose of MK-1006 100 mg</description>
        </group>
        <group group_id="E8">
          <title>MK-1006 140 mg</title>
          <description>Participants received a single dose of MK-1006 140 mg</description>
        </group>
        <group group_id="E9">
          <title>MK-1006 170 mg</title>
          <description>Participants received a single dose of MK-1006 170 mg</description>
        </group>
        <group group_id="E10">
          <title>Placebo</title>
          <description>Participants received matching placebo to MK-1006</description>
        </group>
        <group group_id="E11">
          <title>Placebo Fed</title>
          <description>Participants received matching placebo to MK-1006 following consumption of a standard Japanese breakfast</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

